This guideline covers diagnosing and managing glaucoma in people aged 18 and over. It includes recommendations on testing and referral (case-finding) for chronic open angle glaucoma and ocular hypertension, and on effective diagnosis, treatment and reassessment to stop these conditions progressing.
We have produced a large print version of this guideline, which is available to download in tools and resources.
This guideline includes recommendations on:
- standard practice for all assessments
- organisation of care
- providing information
Who is it for?
- Healthcare professionals
- Commissioners and providers of eye care services
- Adults with chronic open angle glaucoma or ocular hypertension, or who are at risk of developing glaucoma, their families and carers
Is this guideline up to date?
We checked this guideline in September 2019 and we are updating the recommendations following the publication of a Health Technology Assessment report on selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma.
See the guideline in development page for progress on the update.
Guideline development process
This guideline updates and replaces NICE guideline CG85 (April 2009). We have added or updated recommendations on case-finding, reassessment and treatment in sections 1.1, 1.4 and 1.5.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.